%0 Journal Article
%A Bueno Muiño, Coralia
%A Martín, Miguel
%A Monte Millán, María del
%A García Sáenz, José Ángel
%A López Tarruella Cobo, Sara
%T HER2+ Breast Cancer Escalation and De-Escalation Trial Design: Potential Role of Intrinsic Subtyping
%D 2022
%@ 2072-6694
%U https://hdl.handle.net/20.500.14352/71619
%X Classical clinical research has been developed according to immunohistochemical breast cancer subtypes, instead of designing trials specifically for each molecular subtype. Efforts in de-escalating treatment should focus on identifying a subgroup of HER2 oncogene addicted tumours that are especially sensitive to anti-HER2 therapies and, thus, spare unnecessary treatments. A prognostic assay that integrates molecular tumour features with clinical and pathologic variables and accurately defines a group of HER2 addicted tumours remains the best candidate among these strategies.
%~